Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Francisco, California, USA.
Am J Transplant. 2023 Apr;23(4):531-539. doi: 10.1016/j.ajt.2023.01.020. Epub 2023 Feb 4.
Heterogeneous frailty pathobiology might explain the inconsistent associations observed between frailty and lung transplant outcomes. A Subphenotype analysis could refine frailty measurement. In a 3-center pilot cohort study, we measured frailty by the Short Physical Performance Battery, body composition, and serum biomarkers reflecting causes of frailty. We applied latent class modeling for these baseline data. Next, we tested class construct validity with disability, waitlist delisting/death, and early postoperative complications. Among 422 lung transplant candidates, 2 class model fit the best (P = .01). Compared with Subphenotype 1 (n = 333), Subphenotype 2 (n = 89) was characterized by systemic and innate inflammation (higher IL-6, CRP, PTX3, TNF-R1, and IL-1RA); mitochondrial stress (higher GDF-15 and FGF-21); sarcopenia; malnutrition; and lower hemoglobin and walk distance. Subphenotype 2 had a worse disability and higher risk of waitlist delisting or death (hazards ratio: 4.0; 95% confidence interval: 1.8-9.1). Of the total cohort, 257 underwent transplant (Subphenotype 1: 196; Subphenotype 2: 61). Subphenotype 2 had a higher need for take back to the operating room (48% vs 28%; P = .005) and longer posttransplant hospital length of stay (21 days [interquartile range: 14-33] vs 18 days [14-28]; P = .04). Subphenotype 2 trended toward fewer ventilator-free days, needing more postoperative extracorporeal membrane oxygenation and dialysis, and higher need for discharge to rehabilitation facilities (P ≤ .20). In this early phase study, we identified biological frailty Subphenotypes in lung transplant candidates. A hyperinflammatory, sarcopenic Subphenotype seems to be associated with worse clinical outcomes.
异质性衰弱的病理生物学可能解释了衰弱与肺移植结果之间观察到的不一致关联。亚表型分析可以细化衰弱的测量。在一项三中心试点队列研究中,我们使用短体物理表现电池、身体成分和反映衰弱原因的血清生物标志物来衡量衰弱。我们对这些基线数据应用潜在类别建模。接下来,我们用残疾、候补名单除名/死亡和术后早期并发症来测试类别构建的有效性。在 422 名肺移植候选者中,2 类模型拟合最佳(P =.01)。与亚表型 1(n = 333)相比,亚表型 2(n = 89)的特征是全身性和固有炎症(更高的 IL-6、CRP、PTX3、TNF-R1 和 IL-1RA);线粒体应激(更高的 GDF-15 和 FGF-21);肌肉减少症;营养不良;以及较低的血红蛋白和步行距离。亚表型 2 的残疾更严重,候补名单除名或死亡的风险更高(风险比:4.0;95%置信区间:1.8-9.1)。在总队列中,257 人接受了移植(亚表型 1:196;亚表型 2:61)。亚表型 2 需要更多的回手术室(48%比 28%;P =.005)和更长的术后住院时间(21 天[四分位距:14-33]比 18 天[14-28];P =.04)。亚表型 2在无呼吸机天数、需要更多术后体外膜氧合和透析、以及更高的康复设施出院需求方面呈趋势(P ≤.20)。在这项早期研究中,我们在肺移植候选者中发现了生物学衰弱的亚表型。一种高炎症、肌肉减少的亚表型似乎与更差的临床结果相关。